Popular
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Project Oncology®ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Project Oncology®Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
AudioAbstractsAre E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
Treating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
Medical Industry FeatureTreating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CEGDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
- NEW EPISODE
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®When ß-Blockers Fall Short in oHCM: Time for a New Approach?
- NEW EPISODE
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
CardiologyEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®Turning Flares Into Function: Flag Uncontrolled Disease
Early Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
DermatologyEarly Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
Expanding the Role of Hormonal Therapy and Isotretinoin in Acne Care
Clinician's RoundtableExpanding the Role of Hormonal Therapy and Isotretinoin in Acne Care
Clinical Practice
- Allergy and Clinical Immunology
- Anesthesiology
- Cardiology
- Clinical Pharmacology
- Cornea/External Disease
- Critical Care
- Dental
- Dermatology
- Diabetes and Endocrinology
- Emergency Medicine
- Endocrinology
- Gastroenterology and Hepatology
- General Medicine and Primary Care
- General Ophthalmology
- Genetics
- Geriatrics
- Glaucoma
- HIV/AIDS and Infectious Disease
- Hospice and Palliative Medicine
- Hospital Medicine
- Infectious Diseases
- Integrative Medicine
- Men's Health
- Musculoskeletal Disorders
- Nephrology
- Neurology and Neurosurgery
- Neuro-Ophthalmology
- Nutrition
- OB/GYN and Women's Health
- Ocular Immunology
- Ocular Oncology & Pathology
- Oculoplastic Surgery
- Oncology and Hematology
- Ophthalmology
- Optometry
- Orthopedics
- Otolaryngology
- Pain Management
- Pathology and Lab Medicine
- Pediatrics
- Pediatric Ophthalmology
- Podiatry
- Poisoning and Drug Reference
- Preventive Medicine
- Psychiatry and Mental Health
- Public Health
- Pulmonary Medicine
- Radiology
- Rare and Orphan Diseases
- Refractive Management
- Retina/Vitreous
- Rheumatology
- Sleep Medicine
- Sports Medicine
- Surgery
- Transplantation
- Urology
- Vascular Medicine